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Numerous studies have been published on the safety and efficacy of both device types separately, and both technologies have been associated with favorable short-and long-term outcomes (1) (2) (3) (4) (5) (6) (7) . However, comparative data are scarce and have been derived mainly from observational registries (8) (9) (10) (11) .
In CHOICE (Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus
Edwards SAPIEN XT), the first head-to-head trial of balloon-and self-expandable THVs, the use of a balloon-expandable valve resulted in a greater rate of device success than the use of a self-expandable valve, while clinical outcomes at 30 days were comparable (12) . In this report, we describe the 1-year clinical outcomes and echocardiographic findings after TAVR with balloon-and self-expandable valves in the CHOICE trial.
METHODS
STUDY DESIGN AND POPULATION. The study design and patient selection of the CHOICE trial have been previously described (12) . Briefly, this investigatorinitiated, multicenter, randomized controlled trial included 241 patients with symptomatic severe aortic stenosis at high risk for surgical aortic valve replacement undergoing TAVR through the transfemoral route at 5 German centers. Patients had to be anatomically suitable for treatment with both balloon-and self-expandable valves, which was defined as a native aortic valve annulus measuring 20 to 27 mm in diameter on pre-procedural imaging.
Patients with pre-existing aortic bioprostheses and/or contraindications to transfemoral access were excluded. The study was in compliance with the Declaration of Helsinki, the locally appointed ethics committees approved the research protocol, and written informed consent was obtained from all subjects. An independent data-coordinating center, with oversight from a steering committee, conducted the data management and analysis. The members of the steering committee had full access to the data and vouch for the accuracy and completeness of the data and the analyses.
STUDY DEVICES AND PROCEDURE. The devices used in this study and the TAVR procedure have been previously described (12) (13) (14) . The balloon-expandable valve used in this trial (Edwards SAPIEN XT; Edwards Lifesciences, Irvine, California) is a cylindrical cobalt-chromium stent into which 3 leaflets made of bovine pericardium are mounted, whereas the self- STUDY ENDPOINTS. The pre-specified primary endpoint of the CHOICE trial was "device success," as defined by the first Valve Academic Research Consortium (VARC) consensus document (15) and has been previously reported (12) . All patients were followed-up for at least 1 year and had clinical visits and echocardiographic evaluations at 6 months and 1 year. Pre-specified secondary endpoints included cardiovascular mortality, stroke, repeat hospitalization for heart failure, New York Heart Association Abdel-Wahab et al.
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Balloon-Expandable Versus Self-Expandable TAVR randomized to the balloon-expandable valve and 120 patients to the self-expandable valve. All patients received the assigned TAVR device, with no crossovers. Figure 1 shows the study-group assignments and follow-up. All patients were followed-up for 1 year. The overall study population was elderly (mean age 81.5 AE 6.2 years), had severe cardiac symptoms (80.9% were in NYHA functional class III or IV), and had frequent comorbid conditions (63.1% had histories of coronary artery disease, 39.4% had undergone previous percutaneous coronary intervention, 14.1% had undergone previous coronary artery bypass surgery, 17.4% had peripheral vascular disease, and 21.2% had pulmonary disease). The balloonand self-expandable groups were generally well balanced with regard to baseline clinical and echocardiographic characteristics ( Other clinical events are summarized in Table 2 . At 1 year, there was no statistically significant difference in the rate of repeat hospitalization for heart failure between the groups (7.4% in the balloonexpandable group vs. 12.8% in the self-expandable group; RR: 0.58; 95% CI: 0.26 to 1.27; p ¼ 0.19) (Table 2, Figure 3) . Of the 24 patients requiring rehospitalization for heart failure during the follow-up period, 6 had more than mild residual AR after TAVR, all in the self-expandable group (40% of heart failure hospitalizations in this group). Among survivors at 1 Abdel-Wahab et al. A B (A) Cumulative incidence curves for stroke by device type. (B) Cumulative incidence curves for rehospitalization for heart failure by device type.
Events were calculated using Kaplan-Meier methods, and the p values were calculated using log-rank tests. Values are n/N (%). For mortality, patients who died during the first 30 days were excluded. For all other endpoints, patients who either died or had events in the first 30 days were excluded. The p values were obtained using Fisher exact tests.
Abbreviations as in Table 2 .
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